Welcome to our dedicated page for Kiromic Biopharma news (Ticker: KRBP), a resource for investors and traders seeking the latest updates and insights on Kiromic Biopharma stock.
Kiromic BioPharma Inc (KRBP) is a pioneering biopharmaceutical company dedicated to the development of advanced diagnostic and therapeutic solutions specifically targeting solid tumors and hematologic malignancies. Leveraging a robust portfolio of patented cancer-associated biomarkers and small molecules, Kiromic focuses on creating innovative clinical diagnostic tools and personalized immunotherapy strategies designed to improve patient outcomes, reduce suffering, and extend survival times.
Kiromic's core business revolves around its groundbreaking work in developing rapid detection mechanisms for cancer-associated antigens. This early detection capability can lead to earlier diagnoses and more accurate monitoring of patients' responses to treatments, potentially revolutionizing the field of cancer care. The company's cancer-associated biomarkers are instrumental in designing bespoke, cancer-specific targeted immunotherapies that promise higher efficacy and fewer side effects compared to traditional treatments.
Recent achievements by Kiromic BioPharma include significant advancements in their diagnostic and therapeutic programs. The company is actively engaged in several promising projects aimed at enhancing the precision and effectiveness of cancer treatments. Through strategic partnerships and collaborations, Kiromic continues to expand its research and development capabilities, constantly pushing the boundaries of cancer treatment innovation.
Financially, Kiromic BioPharma is committed to maintaining a stable and growing financial health, ensuring the sustainability of its ambitious projects and ongoing research. The company regularly updates stakeholders about its financial performance and significant milestones achieved, ensuring transparency and fostering investor confidence.
Noteworthy projects currently underway include the development of next-generation diagnostic tools that promise greater accuracy in detecting cancer-associated antigens, and the creation of more effective personalized immunotherapy treatments. By focusing on these critical areas, Kiromic aims to make substantial contributions to the field of oncology, offering hope and improved outcomes for cancer patients worldwide.
For the latest updates and relevant information about Kiromic BioPharma, including performance, events, and developments, investors and stakeholders are encouraged to follow the latest news releases.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) announced a two-year sponsored research agreement with Dr. James W. Welsh from The University of Texas MD Anderson Cancer Center. This agreement aims to generate in vivo preclinical data for Kiromic’s Gamma Delta T cell therapies, enabling three new investigational drug (IND) applications to the FDA. The first IND submission, Deltacel™, is expected in the second half of this year, with the initiation of its clinical trial anticipated by year’s end. This addition will expand Kiromic's therapy pipeline to five allogeneic GDT clinical trials.
Kiromic BioPharma (NASDAQ: KRBP) reported significant progress in Q1 2022, focusing on immuno-oncology through its proprietary DIAMOND® AI platform. Key achievements include advancements in the ALEXIS Gamma Delta T cell platform and the redesign of its cGMP manufacturing facility. Financially, the company reported cash reserves of $15.1 million, a decrease from $25.4 million at year-end 2021. R&D expenses rose by 55.2% to $2.9 million, while G&A expenses surged by 114.4% to $4.4 million, leading to a net loss of $7 million, up from $3.9 million in the prior year.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) announces progress addressing FDA CMC issues related to its Investigational New Drug Applications (INDs). The company will submit an amended IND for its oncology cell therapy candidate Procel™ in the second half of 2022, bypassing a planned Type A FDA meeting. Additionally, Kiromic is advancing the establishment of a current good manufacturing practice mammalian master cell bank, a critical component for producing GMP-grade retroviral vectors necessary for Gamma Delta T-cell engineering. CEO Pietro Bersani highlighted these developments as integral to initiating clinical trials for Procel™ by Q4 2022.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) has made its latest corporate presentation available, focusing on its innovative use of the DIAMOND AI platform for developing immuno-oncology therapies. The presentation provides insights into the company’s strategic goals and its allogeneic CAR-T cell therapy platform, ALEXIS. This platform is designed to target solid tumors using gamma delta T-cells. The updated information can be accessed on the investor relations section of Kiromic's website, and the presentation has been filed with the SEC.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) reported substantial advancements in its research and development efforts, particularly in its ALEXIS Gamma Delta T cell platform. The company completed 90% of its cGMP facility expansion and launched DIAMOND® AI 2.0, which now encompasses nearly two billion data points for immunotherapy target identification. For the fiscal year ended December 31, 2021, Kiromic's cash position rose to $25.35 million, while R&D expenses surged by 125% to $11.37 million, contributing to a net loss of $25.59 million, up from $19.20 million the previous year.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) has filed a Form 12b-25 with the SEC seeking a 15-day extension to submit its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The company anticipates that the filing will occur within the extension period. Kiromic focuses on developing cell and gene therapies, leveraging its proprietary DIAMOND® AI platform to target immuno-oncology applications. The firm aims to enhance the development timeline and reduce costs of bringing innovative therapies to market.
Kiromic BioPharma (NASDAQ: KRBP) reported significant advancements in Q3 2021, including an expansion of its DIAMOND® AI platform to over 1.5 billion data points, reflecting a 25% increase. The completion of the InSilico Solutions acquisition, bolstering AI-driven research, and a public offering generating $37.1 million net proceeds were notable highlights. Financially, cash equivalents rose to $36.2 million; however, R&D expenses surged by 184% to $3.5 million, reflecting increased operational costs. The net loss decreased slightly to $14.95 million year-to-date.
Kiromic BioPharma (NASDAQ: KRBP) announces management changes effective
Kiromic BioPharma (NASDAQ: KRBP) has appointed Frank Tirelli as Chair of the Audit Committee and Karen Reeves, M.D. to its Board of Directors. Tirelli, a CPA with extensive experience at Deloitte, is expected to enhance financial reporting capabilities. Reeves brings over 25 years of biopharmaceutical expertise, notably in clinical R&D and regulatory affairs. Both appointments aim to strengthen the board during critical developments in Kiromic's immuno-oncology pipeline, leveraging its proprietary DIAMOND® AI platform for innovative therapies.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) announced it received a notice from Nasdaq on
FAQ
What is the current stock price of Kiromic Biopharma (KRBP)?
What is the market cap of Kiromic Biopharma (KRBP)?
What does Kiromic BioPharma Inc do?
What are Kiromic's core areas of focus?
How does Kiromic's technology improve cancer treatment?
What recent achievements has Kiromic BioPharma made?
How does Kiromic ensure financial stability?
What projects are Kiromic currently working on?
Why are Kiromic's biomarkers important?
How can I stay updated on Kiromic's latest developments?
What is Kiromic's mission?
How does Kiromic contribute to oncology?
